(Q35123575)

6 August 2017

1 reference

title

Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance (English)

1 reference

6 August 2017

Endocrine-resistant breast cancer: Underlying mechanisms and strategies for overcoming resistance (English)

1 reference

31 December 2023

1 reference

31 December 2023

author name string

Junichi Kurebayashi

1

1 reference

6 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12736563

31 December 2023

publication date

1 January 2003

1 reference

full work available at URL

6 August 2017

http://link.springer.com/content/pdf/10.1007/BF02967635.pdf

file format

Portable Document Format

1 reference

http://link.springer.com/article/10.1007/BF02967635/fulltext.html

31 December 2023

1 reference

http://link.springer.com/content/pdf/10.1007/BF02967635

31 December 2023

1 reference

31 December 2023

1 reference

6 August 2017

10

1 reference

6 August 2017

112-119

1 reference

6 August 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1007/bf02967635

6 August 2017

0 references

cites work

Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02967635

pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02967635

Hypoxia reduces hormone responsiveness of human breast cancer cells

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02967635

21 January 2018

Cancer Treatment Reports

1

63

1839

S Legault-Poisson

1979

1 reference

Response after withdrawal of tamoxifen and progestogens in advanced breast cancer

31 December 2023

2

1 reference

Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism

31 December 2023

4

1 reference

Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study

31 December 2023

6

1 reference

Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo

31 December 2023

8

1 reference

Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase

31 December 2023

13

1 reference

Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer

31 December 2023

16

1 reference

Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2.

31 December 2023

19

1 reference

A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I

31 December 2023

20

1 reference

Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance

31 December 2023

21

1 reference

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

31 December 2023

22

1 reference

Ligand-independent activation of the oestrogen receptor by mutation of a conserved tyrosine

31 December 2023

26

1 reference

Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer

31 December 2023

27

1 reference

Expression of alternatively spliced estrogen receptor alpha mRNAs is increased in breast cancer tissues

31 December 2023

31

1 reference

Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer

31 December 2023

32

1 reference

HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF.

31 December 2023

34

1 reference

Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes

31 December 2023

35

1 reference

The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT

31 December 2023

36

1 reference

Estrogen receptor beta expression in invasive breast cancer

31 December 2023

37

1 reference

Estrogen receptors and proliferation markers in primary and recurrent breast cancer

31 December 2023

38

1 reference

Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers.

31 December 2023

39

1 reference

A novel isoform of rat estrogen receptor beta with 18 amino acid insertion in the ligand binding domain as a putative dominant negative regular of estrogen action

31 December 2023

40

1 reference

Current Status and Controversial Issues concerning Endocrine Therapy for Patients with Recurrent Breast Cancer in Japan

31 December 2023

41

1 reference

Distinct mechanisms of loss of estrogen receptor alpha gene expression in human breast cancer: methylation of the gene and alteration of trans-acting factors.

31 December 2023

43

1 reference

Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma

31 December 2023

45

1 reference

Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects

31 December 2023

46

1 reference

Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy.

31 December 2023

47

1 reference

Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer

31 December 2023

48

1 reference

Trastuzumab: hopes and realities

31 December 2023

49

1 reference

Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials

31 December 2023

50

1 reference

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

31 December 2023

51

1 reference

ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer

31 December 2023

52

1 reference

ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer

31 December 2023

53

1 reference

A pilot study of intermittent androgen deprivation in advanced prostate cancer

31 December 2023

57

1 reference

Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study

31 December 2023

58

1 reference

Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia

31 December 2023

59

1 reference

31 December 2023

Identifiers

DOI

10.1007/BF02967635

1 reference

6 August 2017

1 reference